These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9445210)

  • 1. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
    Yang CS; Khawly JA; Hainsworth DP; Chen SN; Ashton P; Guo H; Jaffe GJ
    Arch Ophthalmol; 1998 Jan; 116(1):69-77. PubMed ID: 9445210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
    Cardillo JA; Farah ME; Mitre J; Morales PH; Costa RA; Melo LA; Kuppermann B; Jorge R; Ashton P
    Br J Ophthalmol; 2004 Sep; 88(9):1201-5. PubMed ID: 15317716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye.
    Perkins SL; Gallemore RP; Yang CH; Guo H; Ashton P; Jaffe GJ
    Retina; 2000; 20(5):514-9. PubMed ID: 11039427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR.
    Hegazy HM; Peyman GA; Liang C; Unal MH; Molinari LC; Kazi AA
    Int Ophthalmol; 1998-1999; 22(4):239-46. PubMed ID: 10674869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
    Rubsamen PE; Davis PA; Hernandez E; O'Grady GE; Cousins SW
    Arch Ophthalmol; 1994 Mar; 112(3):407-13. PubMed ID: 8129669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes.
    Oliveira RC; Messias A; Siqueira RC; Bonini-Filho MA; Haddad A; Damico FM; Maia-Filho A; Crispim PT; Saliba JB; Ribeiro JA; Scott IU; Cunha AS; Jorge R
    Curr Eye Res; 2012 Jan; 37(1):55-61. PubMed ID: 22029458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy.
    Kuo HK; Chen YH; Wu PC; Kuo YH
    Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
    Rahimy MH; Peyman GA; Fernandes ML; el-Sayed SH; Luo Q; Borhani H
    J Ocul Pharmacol; 1994; 10(3):561-70. PubMed ID: 7836865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF
    Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.
    Munir WM; Pulido JS; Sharma MC; Buerk BM
    Can J Ophthalmol; 2005 Oct; 40(5):598-604. PubMed ID: 16391623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.
    Khanum BNMK; Guha R; Sur VP; Nandi S; Basak SK; Konar A; Hazra S
    Eye (Lond); 2017 Sep; 31(9):1317-1328. PubMed ID: 28304388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU.
    Borhani H; Peyman GA; Rahimy MH; Thompson H
    Int Ophthalmol; 1995; 19(1):43-9. PubMed ID: 8537196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].
    Jonas JB; Kreissig I; Degenring RF
    Klin Monbl Augenheilkd; 2003 Jun; 220(6):384-90. PubMed ID: 12830391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis.
    Jaffe GJ; Yang CS; Wang XC; Cousins SW; Gallemore RP; Ashton P
    Ophthalmology; 1998 Jan; 105(1):46-56. PubMed ID: 9442778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
    Ahmadieh H; Feghhi M; Tabatabaei H; Shoeibi N; Ramezani A; Mohebbi MR
    Ophthalmology; 2008 Nov; 115(11):1938-43. PubMed ID: 18584876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
    Joondeph BC; Peyman GA; Khoobehi B; Yue BY
    Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
    Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
    Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial.
    Guo H; Yu J; He T; Chen S; Sun Z; Zhang J; Sun Z; Yang W; Yao B; Yang X; Liu Y; Zhang M; Meng Y; Yang L; Yan H
    Br J Ophthalmol; 2024 Jul; 108(8):1161-1167. PubMed ID: 38041678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained release intravitreal dexamethasone.
    Hainsworth DP; Pearson PA; Conklin JD; Ashton P
    J Ocul Pharmacol Ther; 1996; 12(1):57-63. PubMed ID: 8925398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.